Pharmacology, organized the way drugs actually work
13 chapters
·
about 16 min read
·
free
Pharmacology looks like thousands of drug names. It is really two questions you ask about every one of them. What does the body do to the drug? Absorption, distribution, metabolism and excretion together decide how much drug is at the target and for how long. What does the drug do to the body? That is which receptor it occupies, and whether it switches that receptor on or off. Every drug class below answers the second question, and every dosing decision answers the first. Once you hold both frames, a new drug name becomes a placement problem rather than a memorization one. Orientation for study, not clinical advice, and not affiliated with any licensing or certifying body. Nothing here is a basis for treating anyone.
Each chapter opens with the short version. Tap one to read the detail.
What the body does to the drug
~2 min
Absorption, distribution, metabolism and excretion decide how much drug reaches its target and for how long. Almost every practical difference you will meet between two routes or two doses traces back to one of the four.
Pharmacokinetics is one pipeline with four stages, and each stage explains a family of facts that would otherwise look arbitrary to you.
Absorption depends on route. A swallowed drug must cross the gut wall and pass through the liver before it reaches the general circulation, so a portion is removed before it ever acts. That is why an oral dose of a given drug is often far larger than the intravenous one. Routes that bypass that path, including intravenous, reach the circulation directly.
Distribution then decides where the drug goes. Much of it travels bound to plasma protein, and bound drug is inactive. Only the free fraction can act, which is why protein binding matters when two drugs compete for the same sites.
Metabolism, largely hepatic, converts drugs into forms that can be cleared, and excretion, largely renal, removes them. Reduced kidney function therefore prolongs a drug's stay in the body without anything about the dose changing.
The misconception is that a dose is a quantity of effect. It is a quantity of substance entering a pipeline, and how much reaches the target depends on every stage after it. That is why two routes, or two people, turn the same number into different outcomes.
Concretely: give the same milligram dose orally and intravenously and you get different blood levels; the difference is first-pass metabolism, not a measurement error.
Rule: when a dosing fact looks arbitrary, ask which of the four stages it is a consequence of.
What the drug does to the body
~2 min
Most drugs work by occupying a receptor. An agonist binds to produce the desired effect; an antagonist competes for the same site and blocks it. Adverse effects usually come from the same mechanism acting where it was not wanted.
Pharmacodynamics reduces to a small vocabulary you can learn in a sitting. An agonist binds tightly to a receptor to produce a desired effect. An antagonist competes with other molecules for that receptor, occupying it without producing the effect, which is how a blocking drug works at all.
The dose-response relationship gives you the second key idea: the therapeutic index, the effective dose range between too little and too much. A wide index is forgiving. A narrow one means the useful dose and the harmful dose sit close together, which is what makes certain drugs demand monitoring.
The misconception worth dismantling is that side effects are separate from the drug's action. Usually they are the same action in the wrong tissue. A drug that blocks a receptor in the heart blocks the same receptor wherever else the body uses it. The unwanted consequences follow from that, not from impurity or bad luck.
Concretely: a drug that relaxes airway smooth muscle by acting on a receptor family also present in the heart can raise heart rate. What you are seeing is one mechanism in two tissues, with one desired outcome and one unwanted.
Rule: predict a drug's adverse effects by asking where else its target receptor lives.
The autonomic nervous system is the master key
~2 min
The autonomic nervous system balances sympathetic and parasympathetic activity across heart rate, breathing, digestion and secretions. An enormous fraction of drug classes work by pushing or blocking one of those two branches.
The autonomic nervous system regulates involuntary functions such as heart rate, respiratory rate, digestion and sweating. It does so through a balance of its sympathetic and parasympathetic branches. Learn this once and a large share of pharmacology becomes something you derive rather than memorize.
Four moves exist, and every autonomic drug is one of them: stimulate the parasympathetic system, block it, stimulate the sympathetic system, or block it. The two branches oppose each other across most organs, so blocking one resembles stimulating the other. That is why superficially unrelated drug classes produce overlapping effects.
The misconception is that you must learn these drug families organ by organ. Learn them branch by branch instead. Once you know what sympathetic activation does to the heart, the gut and the airways, the effects of a drug that stimulates it are a lookup rather than a list.
Concretely: a drug blocking parasympathetic activity dries secretions, speeds the heart and slows the gut. Those are three effects in three organs from a single mechanism, and you can predict all three before you have seen the drug's name.
Rule: identify the branch and the direction first; the organ-by-organ effects follow from the physiology.
Cardiovascular drugs: pressure, rate, rhythm
~2 min
Cardiovascular pharmacology addresses a small number of levers: how hard the heart works, how much fluid it moves, how wide the vessels are, and how electrical signals propagate. Each drug class pulls one of them.
Cardiovascular drugs look numerous, and they are organized by lever. Pressure can be lowered by relaxing vessels, by reducing circulating volume, or by reducing the drive on the heart itself. Rate and rhythm are separate problems, addressed by drugs acting on cardiac electrical conduction.
Grouping by lever is what makes the classes tractable for you: two drugs from different families that both relax vessels will share a family of consequences. That includes the ones you do not want, such as pressure falling too far when the patient stands.
The misconception is that you choose cardiovascular drugs by disease name. They are chosen by which lever the physiology needs moved. That is why the same agent appears under several conditions, and why two drugs for "high blood pressure" can behave quite differently.
Concretely: one drug lowers pressure by reducing circulating volume, and another by relaxing vessels. Both reduce a number on a monitor, but they reach it by different physiology. Their other effects, and the situations where each is unsuitable, differ completely.
Rule: name the lever before the class, and the class's other effects stop being surprises.
Drugs that act on clotting
~2 min
Anticoagulants, antiplatelets and thrombolytics all reduce clotting, and they do it at different points in the process. That is why they are monitored differently and are not interchangeable.
Clot formation is a sequence, and each drug family interrupts a different step. Antiplatelet agents act on the platelets that begin a clot. Anticoagulants act on the cascade of factors that stabilize it. Thrombolytics break down a clot that has already formed.
That ordering explains why the monitoring you will read about differs. A drug acting on one part of the cascade is followed by the laboratory test that measures that part. A drug acting elsewhere needs a different test or none, so "checking the clotting" is not one activity.
The misconception is that these are three strengths of the same thing: a mild, a moderate and a strong blood thinner. They are three different mechanisms. When you compare them, the question is which step of the process needs interrupting, not which is more potent.
Concretely: a patient can be fully treated with an agent acting on platelets and still form a clot through the coagulation cascade, because the drug never touched that pathway.
Rule: place any clotting drug on the sequence — platelets, cascade, or breakdown — before you compare it with another.
Anti-infectives: mechanism, then spectrum
~2 min
Antibacterials are grouped by whether they kill organisms or merely stop them multiplying, and by which cellular machinery they attack: cell wall, protein synthesis, or nucleic acids. Antifungals, antivirals and antiparasitics extend the same logic to other organisms.
Antibiotics are selected on two axes at once. One is whether their action is bacteriostatic or bactericidal; the other is their mechanism of action. Both matter, and the second is what organizes the classes you will study.
Agents attacking the bacterial cell wall exploit a structure human cells do not have, which is why that mechanism is comparatively well tolerated. Others interfere with bacterial protein synthesis or with nucleic acid processes. Antifungals, antivirals and antiparasitics apply the same reasoning to organisms whose biology resembles ours more closely. That is precisely why those agents tend to be harder on the patient.
The misconception is that a "stronger" antibiotic is a better one. Spectrum is not strength. An agent covering more organisms also disturbs more of the body's own flora and applies broader selection pressure toward resistance.
Concretely: two agents can treat the same infection while attacking entirely different bacterial machinery. An organism resistant to one may therefore remain fully susceptible to the other.
Rule: identify the mechanism and the target's biology, and you can work out both the tolerability and the resistance story.
Central nervous system drugs
~1 min
Sedatives, anxiolytics, antiepileptics and drugs for neurodegenerative disease mostly work by shifting the balance between the nervous system's excitatory and inhibitory signaling.
Central nervous system pharmacology gives you one unifying idea. The nervous system runs on a balance between signals that excite neurons and signals that inhibit them, and most CNS drugs push that balance one way.
Sedatives and anxiolytics enhance inhibitory signaling. That is why sedation, reduced anxiety and impaired coordination tend to arrive together: they are one effect measured three ways. Antiepileptics reduce excessive excitation or reinforce inhibition, which is the same axis approached from the other side.
The misconception is that "central nervous system depressant" describes a category of drug. It describes a direction, and drugs from unrelated families all move in it. Their effects therefore add up in a patient taking several, and that additivity is the clinically important fact about them.
Concretely: two drugs with different indications and unrelated chemistry can both enhance inhibitory signaling, and their sedative effects combine even though neither was given for sedation.
Rule: ask which way a CNS drug moves the excitation-inhibition balance, then ask what else the patient is taking that moves it the same way.
Psychotropic medication classes
~2 min
Antidepressants, antipsychotics and mood stabilizers are grouped by the neurotransmitter systems they modulate. Their defining practical feature is that effects build over weeks, unlike most of pharmacology.
Psychotropic classes are organized by which neurotransmitter systems they act on. The mechanistic frame from earlier chapters transfers directly: these are receptor and reuptake effects, with adverse effects arising where the same systems operate elsewhere.
What sets the category apart is time. Most of pharmacology is fast: give a drug, observe an effect. Several psychotropic classes produce their intended benefit only after sustained use over weeks, while their side effects can appear immediately. That asymmetry is the single most important structural fact you should know about them.
The misconception follows directly: that if you see no early effect, the drug is not working. For several classes, early absence of benefit alongside early side effects is the expected pattern, not evidence of failure.
Concretely: a person may notice unwanted effects within days while the intended benefit is still weeks away. That is exactly the window in which medication is most often abandoned.
Rule: for any psychotropic, ask separately how fast the benefit arrives and how fast the adverse effects do — the two answers are usually different.
Orientation for study, not clinical advice. Psychiatric medication decisions belong with a qualified prescriber who knows the individual.
Pain: opioid and non-opioid routes
~2 min
The body has its own opioid system, and opioid drugs act on those receptors to inhibit how pain signals are perceived and transmitted. Non-opioid analgesics work elsewhere, which is why combining routes achieves more than raising one dose.
Pain relief divides by where in the pain pathway a drug acts. The body produces its own opioid peptides, namely endorphins, enkephalins and dynorphins. They interact with opioid receptors to inhibit the perception and transmission of pain signals, and opioid drugs act on that existing system.
Non-opioid analgesics work by different routes, several of them by reducing the inflammatory signaling that generates pain in the first place. Because the mechanisms differ, you can think of agents from the two groups as addressing the same pain through independent pathways.
The misconception is that analgesia is a single ladder of strength, with each step simply stronger than the last. It is not. Two mechanisms acting at different points can accomplish what raising one drug's dose cannot, and the adverse effects that limit each are entirely different.
Concretely: pain that persists on a large dose of one agent may respond when a second, differently-acting agent is added. The pain did not "need more"; a second pathway was untouched.
Rule: locate the drug on the pain pathway before you compare its strength with anything else.
Endocrine drugs replace, suppress, or mimic
~2 min
Endocrine pharmacology does three things: replace a hormone the body is not making, suppress one it is overproducing, or mimic a hormone's action for an unrelated purpose. Corticosteroids are the clearest case of the third.
You can hold endocrine drugs most easily as three intentions. Replacement supplies a hormone the body no longer makes in sufficient quantity. Suppression reduces one being overproduced. Mimicry uses a hormone's effects deliberately for a purpose other than correcting a deficiency.
That third intention explains corticosteroids. They are given for their anti-inflammatory and immune-suppressing effects rather than to correct a hormonal shortfall, and that explains why their unwanted effects are so wide-ranging. A hormone acts on many tissues by design, so using it for one of its effects necessarily delivers the others.
The misconception is that hormonal drugs are targeted, the way you might expect a modern drug to be. Hormones are the body's least targeted signaling system: they travel everywhere and act wherever a receptor exists.
Concretely: a drug given for its effect on inflammation also affects glucose handling, bone and the immune response. Those are not side effects in the incidental sense; they are all things that hormone does.
Rule: ask which of the three intentions a hormonal drug serves, then expect its other effects to follow the hormone's normal reach.
Airways and gut: local targets, systemic reach
~2 min
Respiratory and gastrointestinal drugs are often delivered straight to the organ that needs them, which limits systemic exposure. The receptors they act on exist elsewhere, though, so the reach is never zero.
These two systems share a delivery idea: put the drug where it is needed. Inhaled agents reach the airways directly, and several gastrointestinal drugs act in the gut lumen. Local delivery means a smaller dose achieves an effect at the target, and less drug circulates.
But the receptors do not stop at the organ. An inhaled drug acting on receptors in the airway acts on the same receptors elsewhere, in whatever fraction is absorbed. That is why systemic effects appear at higher doses, and why the technique of delivery genuinely matters.
The misconception is that local delivery means local effect. It means a favorable ratio, not an absolute boundary, and you see the difference exactly when the dose rises.
Concretely: an inhaled drug that relaxes airway muscle can produce a noticeable tremor or a faster heartbeat, because the absorbed fraction reaches the same receptor family in muscle and heart.
Rule: treat local delivery as a dose advantage, never as containment — then predict the systemic effects from the receptor, as everywhere else.
Populations, regulation, and where this guide stops
~2 min
Dose is not a property of a drug alone; it depends on the person's organ function, body composition and stage of life. Around all of it sits a regulatory system governing how drugs are approved, labeled and monitored.
Everything you met in the pharmacokinetics chapter varies between people. Kidney and liver function determine clearance, so the same dose behaves differently in two individuals. Body composition changes how a drug distributes, and the extremes of age differ from the middle for both reasons at once.
Around the pharmacology sits a system. Drugs are approved on evidence, labeled with required information, and monitored after release, because effects too rare to appear in trials emerge only in wide use. That post-market stage is why a drug's safety picture can change years after approval.
The misconception is that the published dose you look up is a property of the drug. It is a starting point calibrated to a typical adult with typical organ function, and the person's physiology decides what that dose does.
Concretely: an unchanged dose can accumulate to harmful levels purely because clearance has declined. Nothing about the prescription changed, and the drug is behaving exactly as the pharmacokinetics predict.
Rule: ask what this person's clearance and composition do to the four stages before you treat any published number as settled.
Two topics sit deliberately outside the main chapters of this guide: antineoplastic and immunomodulator pharmacology, and toxicology and antidote management. They are high-consequence specialties with no free, openly licensed source established for them yet, so you get only the brief orientation in the next chapter. They are named here so you can see the gap rather than miss it.
Narrow margins: cytotoxics and overdose
~2 min
Antineoplastics and overdose management share one property that dominates both: the gap between an effective amount and a harmful one is small. Dose precision and monitoring stop being administrative and become the substance of the work.
Two areas sit apart from the rest of the pharmacology you have studied, because their therapeutic index is narrow.
Cytotoxic drugs act on rapidly dividing cells. That is what makes them useful against tumors, and it is also what makes them affect the body's own fast-dividing tissues: the lining of the gut, blood-forming marrow, hair follicles. The mechanism and the toxicity are the same fact, more tightly coupled than anywhere else in this guide.
Overdose management runs the same idea backwards: an amount that was therapeutic becomes harmful, and the response depends on which mechanism is doing the harm. Some agents have a specific antidote that reverses the mechanism. Most do not, and support of the affected system is all there is.
The misconception is that an antidote exists for most substances. Specific antidotes are the exception, not the rule.
Concretely: two overdoses of similar size can need completely different responses, because what matters is the mechanism of harm rather than the quantity taken.
Rule: where the therapeutic index is narrow, treat monitoring as part of the mechanism rather than as paperwork around it.
Orientation for study, not clinical advice. This chapter is deliberately brief: it orients you to both specialties rather than teaching them, and it carries no further-reading link because no free, openly licensed source has been established for either specialty.
Written by Keentune. We are not affiliated with or endorsed by the organizations whose documentation informs this guide, and any linked sources belong to their respective owners.
All exam, test, and product names and trademarks are the property of their respective owners and are used here for identification and reference only. Keentune is independent study practice — not affiliated with, authorized, or endorsed by any of these organizations.